Thymosin alpha-1 is a master immune regulator: it promotes T-cell differentiation and activates dendritic cells, NK cells, and cytotoxic T-lymphocytes. It is approved in more than 35 countries as Zadaxin for hepatitis, cancer, and immune deficiency. It is not approved in the US.
- Approved in 35+ countries as Zadaxin for hepatitis, cancer, and immune deficiency.researchdosing
- Promotes T-cell differentiation and activates dendritic cells, NK cells, and cytotoxic T-lymphocytes.researchdosing
- Modulates Th1/Th2 balance.researchdosing
- Used clinically as an adjunct to antiviral therapy for chronic hepatitis B and C in countries where Zadaxin is approved; described as synergistic rather than antagonistic.researchdosing
- CD4/CD8 ratio and NK counts are measurable endpoints; generally very well tolerated, with rare injection-site reactions.researchdosing